Accéder au contenu
Merck

TRAF4 regulates ubiquitination-modulated survivin turnover and confers radioresistance.

International journal of biological sciences (2024-01-02)
Jinzhuang Liao, Xiang Qing, Xiaoying Li, Yu Gan, Ruirui Wang, Shuangze Han, Wei Li, Wei Song
RÉSUMÉ

Nasopharyngeal carcinoma (NPC) is the most common cancer originating in the nasopharynx. Despite continuous improvement in treatment strategies, recurrence or persistence of cancer after radiotherapy is still inevitable, highlighting the need to identify therapeutic resistance factors and develop effective methods for NPC treatment. Herein, we found that TRAF4 is overexpressed in NPC cells and tissues. Knockdown TRAF4 significantly increased the radiosensitivity of NPC cells, possibly by inhibiting the Akt/Wee1/CDK1 axis, thereby suppressing survivin phosphorylation and promoting its degradation by FBXL7. TRAF4 is positively correlated with p-Akt and survivin in NPC tissues. High protein levels of TRAF4 were observed in acquired radioresistant NPC cells, and knockdown of TRAF4 overcomes radioresistant in vitro and the xenograft mouse model. Altogether, our study highlights the TRAF4-survivin axis as a potential therapeutic target for radiosensitization in NPC.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-TRAF4 Antibody, clone 5MLN-2H1, ascites fluid, clone 5MLN-2H1, from mouse